

28
over

414, 416, 419, 430, 434, 435, 437, 438 or 439 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

Please cancel claim 3 without prejudice or disclaimer.

Please add the following claims:

50. (New) A polypeptide comprising a variant Fc region, which polypeptide comprises an amino acid modification at any one or more of amino acid positions 256, 290, 298, 312, 326, 330, 333, 360, 378 or 430 of the Fc region, wherein the numbering of the residues in the Fc region is that of the EU index as in Kabat.

51. (New) The polypeptide of claim 50 which comprises two or more amino acid substitutions at the amino acid positions listed therein.

B3

52. (New) The polypeptide of claim 50 which comprises three or more amino acid substitutions at the amino acid positions listed therein.

53. (New) The polypeptide of claim 50 which comprises an antibody.

54. (New) The polypeptide of claim 50 which comprises an amino acid substitution at position 298.

55. (New) The polypeptide of claim 50 which comprises an amino acid substitution at position 333.

56. (New) The polypeptide of claim 50 which comprises amino acid substitutions as two or three of positions 298, 333 and 334.

57. (New) The polypeptide of claim 56 which comprises amino acid substitutions at positions 298, 333, and 334.

58. (New) The polypeptide of claim 57 which consists of amino acid substitutions at positions 298, 333, and 334.

59. (New) The polypeptide of claim 50 which comprises a variant human IgG1, IgG2, IgG3 or IgG4 Fc region.

60. (New) The polypeptide of claim 59 which comprises a variant human IgG1 Fc region.

61. (New) A variant of a parent polypeptide comprising a human IgG Fc region, which variant binds an Fc gamma receptor III (FcγRIII) with better affinity than the parent polypeptide and comprises two or more amino acid substitutions in the Fc region.

3
Comp